|
1599 |
Microbiotix, Inc. |
|
2HRZE 2HR |
|
|
Actinomycete metabolites |
|
|
Adamantanids |
|
|
Alpibectir (BVL-GSK098) |
BioVersys AG, GlaxoSmithKline |
|
Amidino-urea 8918 |
Weill Medical College of Cornell University, NIAID, NIH, DHHS |
|
ATP Synthesis Inhibitors |
TB Alliance, University of Auckland |
|
Auranofin |
The Aurum Institute NPC, Calibr, The Scripps Research Institute |
|
AZD5847 |
AstraZeneca |
|
Bedaquiline |
Janssen Research & Development, LLC |
|
Benzofuroxan |
São Paulo State University (UNESP) |
|
Bi-functional Molecules |
|
|
Bortezomib |
SPRINT TB (National University of Singapore) |
|
BRD4592 |
The Broad Institute |
|
BTZ-043 |
University of Munich, Hans-Knöll Institute, Jena, German Center for Infection Research (DZIF), European and Developing Countries Clinical Trials Partnership (EDCTP), Radboud University |
|
CC-11050 |
The Aurum Institute NPC, Medicines Development for Global Health |
|
Celecoxib |
|
|
Celecoxib WBA |
|
|
CLB073 |
Bill & Melinda Gates Medical Research Institute |
|
Clofazimine |
Novartis |
|
Contezolid (MRX-4/MRX-1) |
MicuRx Pharmaceuticals, Inc. |
|
CPZEN-45 |
|
|
Cyclopeptides |
|
|
DC-159a |
|
|
Delamanid |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
|
Delpazolid (LCB01-0371) |
LegoChem Biosciences, Inc. |
|
DNA metabolism |
|
|
DprE Inhibitors |
|
|
DprE1 Inhibitors |
Calibr, The Scripps Research Institute |
|
EMB |
|
|
Energy Metabolism Inhibitors |
|
|
Everolimus |
The Aurum Institute NPC |
|
Faropenem WBA |
|
|
FNDR 20364 |
|
|
FNDR-20081 |
Foundation for Neglected Disease Research |
|
Folate Biosynthesis Inhibitors |
|
|
Ganfeborole (GSK 3036656) |
GlaxoSmithKline, European Union Horizon 2020, NIAID, NIH, DHHS |
|
Gatifloxacin |
|
|
GSK 724A (DG167) |
GlaxoSmithKline, Rutgers, The State University of New Jersey |
|
GSK-286 |
GlaxoSmithKline, TB Drug Accelerator, Bill & Melinda Gates Foundation |
|
GSK-693 |
|
|
GSK839 |
GlaxoSmithKline |
|
GSK839 |
GlaxoSmithKline |
|
Gyrase B Inhibitor
|
|
|
GyrB Inhibitors |
|
|
HE2000 |
|
|
HMG-CoA Reductase Inhibitors |
|
|
Hsp65 DNA |
|
|
Imatinib |
|
|
Immunoxel |
|
|
IMPDH Inosine monophosphate dehydrogenase inhibitors |
|
|
Indazoles |
GlaxoSmithKline, TB Alliance |
|
Indolcarboxamides |
TB Alliance |
|
Indoles |
|
|
Inhibitors of DosRST signaling and persistence |
Michigan State University |
|
Inhibitors of isoprenoid biosynthesis |
|
|
Isoniazid |
|
|
JSF-3285 |
|
|
LeuRS inhibitors |
GlaxoSmithKline, Anacor Pharmaceuticals |
|
Levofloxacin |
CDC TBTC, NIAID, NIH, DHHS, Boston University |
|
Linezolid |
|
|
Macozinone (MCZ, PBTZ-169) |
Nearmedic Plus LLC |
|
Macozinone (MCZ, PBTZ-169) |
iM4TB - Innovative Medicines for Tuberculosis, Bill & Melinda Gates Foundation |
|
Macrolides |
|
|
Malate Synthase Inhibitors |
|
|
MBX-4888A |
Microbiotix, Inc. |
|
Menaquinone Synthase Inhibitors |
|
|
Meropenem / Clavulanate |
|
|
Metformin |
|
|
Moxifloxacin |
TB Alliance |
|
Moxifloxacin for Drug-Sensitive TB |
|
|
MTopo |
|
|
Mycobacterial Gyrase Inhibitors |
|
|
Nitazoxanide |
Weill Medical College of Cornell University |
|
Novel hit-lead programs |
|
|
NTB-3119 |
Institute of Materia Medica |
|
Optimized Background Regimen (OBR) |
|
|
OTB-658 |
Institute of Materia Medica, CAMS & PUMC |
|
Phenotypic Hit-to-Lead |
|
|
PKS13 Inhibitors - Coumestan Derivatives |
|
|
PKS13 Inhibitors - TAM16 |
|
|
Pravastatin |
NIAID, NIH, DHHS |
|
Pretomanid |
TB Alliance |
|
Protein Splicing Inhibitors |
|
|
Pyrazinamide |
|
|
Pyrazinamide Analogs |
|
|
Pyridomycin |
|
|
Quabodepistat (OPC-167832) |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
|
Quinolone TBK-613 |
|
|
Rifabutin |
|
|
Rifafour |
|
|
Rifampicin |
PanACEA, EDCTP, NIAID, NIH, DHHS, USAID |
|
Rifapentine |
CDC TBTC, Sanofi |
|
RNA Polymerase Inhibitors |
|
|
Ruthenium (II) phosphine/diimine/picolinate complexes |
|
|
S-004992 |
Shionogi & Co., Ltd |
|
Sanfetrinem |
GlaxoSmithKline, Bill & Melinda Gates Foundation |
|
SATB-082 |
Sanofi, TB Alliance |
|
SPR-113 |
|
|
SPR720 (Fobrepodacin) |
Spero Therapeutics, LLC, Bill & Melinda Gates Medical Research Institute |
|
SQ109 |
Sequella, Inc |
|
SQ609 |
Sequella, Inc |
|
SQ641 |
|
|
Sudapyridine (WX-081) |
Shanghai Jiatan Biotech Ltd., subsidiary of Guangzhou JOYO Pharma Ltd., Shanghai, China |
|
Sulfolane |
GlaxoSmithKline |
|
Sutezolid |
Sequella, Inc, TB Alliance |
|
TB Respiratory Chain |
CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson |
|
TB47 |
Guangzhou Institute of Respiratory Medicine Company Limited, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China |
|
TBA-354 |
TB Alliance |
|
TBA-7371 |
TB Alliance, Bill & Melinda Gates Medical Research Institute, Foundation for Neglected Disease Research |
|
TBAJ-587, Diarylquinoline |
TB Alliance, ERA4TB (European Regimen Accelerator for Tuberculosis), University of Auckland, Merck & Co., Inc. |
|
TBAJ-876 |
TB Alliance, University of Auckland |
|
TBD09 (MK7762) |
Bill & Melinda Gates Medical Research Institute, Merck & Co., Inc., NIAID, NIH, DHHS |
|
TBI-166 |
Institute of Materia Medica, CAMS & PUMC |
|
TBI-223 |
TB Alliance, Institute of Materia Medica |
|
Telacebec (Q203) |
Qurient Co., Ltd, Qurient Co. Ltd. / LLC "Infectex", a portfolio firm of Maxwell Biotech Venture Fund |
|
TGF-B inhib +Cox 2 inhibitor |
|
|
Thioridazine |
|
|
TL1 Inhibitors |
|
|
Trisubstituted benzimidazoles |
|
|
Tryptanthrins |
|
|
TZY-5-84 |
|
|
Ureas |
|
|
Vitamin B6 |
|
|
Vitamin D3 |
The Aurum Institute NPC |
|
Whole cell fragment screens |
|
|
Whole Cell Hit-to Lead |
|
|
Whole cell pathway screens |
|
|
Whole-Cell Hit-to-Lead |
|
|
Xanthones |
|
